Media
Conferences
Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Resources
Clinical
Supplement Spotlight
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
CE
Subscribe
Advertisement
Opinion
Video
Final Thoughts
The panel discussion concludes with final thoughts on the future landscape of newly diagnosed multiple myeloma.
EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM
EP: 2.Frontline Treatment and Sequencing Therapy
EP: 3.Impact of Transplant Eligibility on Treatment Selection
EP: 4.Treatment Regimen Considerations
EP: 5.Impact of IFM 2009 and DETERMINATION Studies
EP: 6.Key End Points in Clinical Trials
EP: 7.Real-World Considerations for New Therapies
EP: 8.Challenges in Adopting Novel Therapies
EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7
EP: 10.Impact of SC Daratumumab
EP: 11.SC vs IV Administration Methods
EP: 12.Pharmacists’ Roles in MM Management
EP: 13.Pharmacists’ Roles on the Multidisciplinary Team
EP: 14.Personalizing Treatments and Patient Education
EP: 15.Addressing Payer Coverage Challenges
EP: 16.Unmet Needs for Transplant-Eligible NDMM
Now Viewing
EP: 17.Final Thoughts
Related Videos
Related Content
Advertisement
Related Content
Advertisement
Contact Info
2 Commerce Drive
Cranbury, NJ 08512
© 2025 MJH Life Sciences
All rights reserved.
All rights reserved.